CClinicalTrials.gg
Not yet recruitingNCT07658235MOP-PBMTUpdated Jun 18, 2026

Micro-osteoperforation Versus Photobiomodulation Therapy for Accelerating Maxillary Canine Retraction

An interventional study of Micro-osteoperforation (MOP) and Photobiomodulation Therapy using 976 nm Diode Laser in Malocclusion, Orthodontic Tooth Movement and Maxillary Canine Retraction, sponsored by Kufa University. Not yet recruiting at 1 site in Iraq. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Kufa University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Orthodontic treatment often requires moving the upper canine teeth (the pointed teeth) into the spaces left after removing premolar teeth. This process is usually slow and can take many months, making the total treatment time longer.This study will compare two techniques that may speed up this tooth movement:

Micro-osteoperforation (MOP): A minimally invasive procedure in which a small device is used to create tiny holes in the jawbone near the canine tooth under local anesthesia. These micro-perforations stimulate the bone to remodel faster, which allows the tooth to move more quickly.

Photobiomodulation therapy (PBMT) / Low-Level Laser Therapy (LLLT): A painless, non-invasive technique that uses a low-power laser light applied to the gum tissue near the canine tooth. The laser energy stimulates cells in the bone and supporting tissues to accelerate tooth movement without any cutting or drilling.

This trial will randomly assign eligible patients into one of three groups: MOP, LLLT, or a control group receiving standard orthodontic treatment only. Each group will contain 25 participants (75 total). The main goal is to measure and compare how fast the upper canine tooth moves in each group over the first month and until the space is fully closed. The study will also measure the effect of age and sex on the results. The findings will help orthodontists choose the best, fastest, and most comfortable method for each patient to shorten overall treatment time

Read the detailed description

Background:

Maxillary canine retraction following first premolar extraction represents the most time-consuming phase of fixed orthodontic therapy, often requiring five to eight months under conventional mechanics. Prolonged treatment duration is associated with increased risks of root resorption, periodontal deterioration, white spot lesions, and reduced patient compliance. Several adjunctive techniques have been proposed to accelerate orthodontic tooth movement (OTM), of which micro-osteoperforation (MOP) and photobiomodulation therapy (PBMT) have demonstrated the most consistent clinical evidence. However, no randomized controlled trial has directly compared these two modalities against each other and against a conventional control under standardized conditions.

Rationale for study design:

A three-arm parallel-group randomized controlled clinical trial (RCT) design was selected in preference to a split-mouth design. Although split-mouth designs offer statistical efficiency, the comparison of MOP and PBMT in a split-mouth model is methodologically inappropriate due to: (1) the risk of contralateral biological cross-contamination from the Regional Acceleratory Phenomenon (RAP) induced by MOP; (2) the potential for sub-therapeutic photon scatter from LLLT irradiation reaching contralateral tissues; and (3) the ethical concern of exposing individual patients to two mechanistically distinct and invasive/non-invasive interventions simultaneously. A parallel-arm design with a true control group eliminates these confounders and allows independent evaluation of each intervention's efficacy.

Objectives:

Primary: To compare the rate of maxillary canine retraction (mm/month) at one month and among patients receiving MOP, PBMT/LLLT, or conventional orthodontic treatment alone.

Secondary: To compare total space-closure duration (months)

Participants:

Seventy-five systemically healthy adults (aged 18-40 years) requiring bilateral maxillary first premolar extraction and fixed orthodontic therapy will be recruited from the Department of Orthodontics. Participants will be equally randomized to one of three groups (n = 25 each) using a computer-generated randomization sequence stratified by age (≤25 / >25 years) and sex.

Interventions:

Group A - MOP: Micro-osteoperforations will be performed under local anesthesia using a PROPEL device (or equivalent). Three perforations of 3 mm depth will be placed mesial and three distal to each maxillary canine (six total per side) at baseline and repeated every four weeks until space closure.

Group B - PBMT/LLLT: A 976 nm diode laser (Woodpecker LX16 Plus or equivalent) will be applied at 8 J/cm², 0.13 W, continuous-wave mode at six mucosal sites per canine (three buccal, three palatal) on days 0, 3, 7, and 14, then every two weeks until space closure.

Group C - Control: Standard orthodontic canine retraction using identical elastomeric power chain force (150 g) without any adjunctive intervention.

All groups will use standardized elastomeric power chain force of 150 g, recalibrated at each monthly visit. Teeth will be retracted on 0.019 × 0.025-inch stainless steel archwires with maximum anchorage (skeletal anchorage via miniscrews or equivalent).

Outcome measurement:

The primary outcome (canine movement in mm) will be measured by a single blinded examiner using a digital Vernier caliper (±0.01 mm precision) on dental study models obtained at baseline, one month, and at space-closure completion.

Sample size:

Based on a weighted mean difference of 0.40 mm in canine movement between MOP/LLLT and control groups, a pooled standard deviation of 0.50 mm, α = 0.05, and 80% power for a one-way ANOVA comparison, 21 participants per group are required. Rounding up to 25 per group accommodates a 20% dropout rate, giving a total sample of 75 participants.

Statistical analysis:

One-way ANOVA with post-hoc Tukey's test for continuous normally distributed outcomes; Kruskal-Wallis test for non-normal outcomes; repeated-measures ANOVA for time-dependent data; Pearson or Spearman correlation for age and sex analyses. Significance set at p ≤ 0.05. Intention-to-treat analysis will be the primary analysis, with per-protocol analysis as a sensitivity check.

Ethics and registration:

Ethical approval obtained from the Institutional Review Board before recruitment. Written informed consent will be obtained from all participants. The trial is prospectively registered on ClinicalTrials.gov prior to enrollment of the first participant, in compliance with ICMJE guidelines and publication requirements.

02

Conditions studied

  • Malocclusion
  • Orthodontic Tooth Movement
  • Maxillary Canine Retraction

Browse trials for

Keywords

  • Micro-osteoperforation
  • Photobiomodulation therapy
  • low-level laser therapy
  • acceleration of tooth movement
03

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 18 to 40 years at the time of enrollment
  • Systemically healthy with no chronic medical conditions affecting bone metabolism or wound healing
  • Requiring bilateral maxillary first premolar extraction as part of a comprehensive fixed orthodontic treatment plan
  • Class I or mild Class II malocclusion requiring maximum anchorage canine retraction
  • Fully erupted maxillary permanent dentition with no missing teeth other than planned extraction teeth
  • Good oral hygiene (Plaque Index ≤ 1) and healthy periodontal status (probing depth ≤ 3 mm, no bleeding on probing)
  • No previous orthodontic treatment
  • Willing to attend all scheduled appointments and comply with study protocol
  • Able to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Systemic diseases affecting bone metabolism including osteoporosis, osteopenia, diabetes mellitus, thyroid disorders, or autoimmune conditions
  • Current use of medications affecting bone remodeling including corticosteroids, bisphosphonates, non-steroidal anti-inflammatory drugs (NSAIDs), or vitamin D supplements
  • Current or recent smokers (within the past 6 months)
  • Pregnant or breastfeeding women
  • History of head and neck radiation therapy
  • Periodontal disease or active dental infection at the time of enrollment
  • Skeletal Class III malocclusion or severe Class II requiring surgical intervention
  • Previous orthodontic treatment or orthognathic surgery
  • Craniofacial syndromes or cleft lip and palate
  • Photosensitivity disorders or use of photosensitizing medications (relevant to LLLT group)
  • Coagulation disorders or anticoagulant therapy (relevant to MOP group)
  • Uncooperative patients or those unable to maintain adequate oral hygiene throughout treatment
  • Parafunctional habits such as severe bruxism or tongue thrusting'
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Micro-Osteoperforation (MOP)

    Participants receive bilateral maxillary canine retraction using a standardized elastomeric power chain force of 150 g on 0.019×0.025-inch stainless steel archwires. Micro-osteoperforations are performed under local anesthesia using a PROPEL device (or equivalent). Six perforations of 3 mm depth are placed per canine (3 mesial, 3 distal) at baseline and repeated every 4 weeks until complete space closure.

    Procedure: Micro-osteoperforation (MOP)

  • Experimental
    Photobiomodulation Therapy / LLLT (976 nm)

    Participants receive bilateral maxillary canine retraction using identical mechanics to the MOP group. A 976 nm diode laser (Woodpecker LX16 Plus or equivalent) is applied at 8 J/cm², 0.13 W, continuous-wave mode at 6 mucosal sites per canine (3 buccal, 3 palatal) on days 0, 3, 7, and 14, then every 2 weeks until complete space closure. No anesthesia is required.

    Device: Photobiomodulation Therapy using 976 nm Diode Laser

  • Experimental
    Control (Conventional Orthodontic Retraction)

    Participants receive standard bilateral maxillary canine retraction using a standardized elastomeric power chain force of 150 g on 0.019×0.025-inch stainless steel archwires. No adjunctive intervention is applied. This group serves as the comparator to quantify the absolute acceleration produced by MOP and LLLT.

    Other: Conventional orthodontic canine retraction

Interventions

  • ProcedureMicro-osteoperforation (MOP)

    Six micro-osteoperforations of 3 mm depth are created under local anesthesia (2% lidocaine with 1:100,000 epinephrine) using a PROPEL device or equivalent, with 3 perforations placed mesial and 3 distal to each maxillary canine on the buccal attached gingiva. The procedure is performed at baseline and repeated every 4 weeks until complete extraction space closure. All participants also receive standardized canine retraction using 150 g elastomeric power chain force on 0.019×0.025-inch stainless steel archwires

  • DevicePhotobiomodulation Therapy using 976 nm Diode Laser

    A 976 nm diode laser (Woodpecker LX16 Plus or equivalent) is applied in continuous-wave mode at a power of 0.13 W and energy density of 8 J/cm² per point. Irradiation is delivered at 6 mucosal sites per canine (3 buccal, 3 palatal) with the laser tip held perpendicular to the tissue surface at each point. Sessions are performed on days 0, 3, 7, and 14 after each activation, then every 2 weeks until complete extraction space closure. No anesthesia is required. All participants also receive standardized canine retraction using 150 g elastomeric power chain force on 0.019×0.025-inch stainless steel archwires

  • OtherConventional orthodontic canine retraction

    Standard bilateral maxillary canine retraction is performed using a standardized elastomeric power chain force of 150 g on 0.019×0.025-inch stainless steel archwires. Force is recalibrated at each monthly appointment. No adjunctive biological or physical intervention is applied. This arm serves as the active comparator to quantify the absolute acceleration produced by MOP and LLLT relative to conventional mechanics alone.

05

What researchers measure

Primary outcomes

  1. Rate of maxillary canine retraction

    The amount of maxillary canine distal movement (mm) measured from the CUSP TIP of the canine to the distal contact point of the lateral incisor using a digital Vernier caliper with 0.01 mm precision. Measurements are performed by a single blinded examiner at baseline and one month after initiation of canine retraction.

    Time frame: 12 months

Secondary outcomes

  1. Total space-closure duration

    ription: The total time in months from the start of canine retraction until complete closure of the extraction space, confirmed clinically by the blinded examiner.

    Time frame: 12 months

  2. Influence of sex on rate of canine retraction

    Independent-samples t-test comparison between male and female participants for two outcome measures: (1) the amount of canine distal movement (mm) at one month, and (2) the total space-closure duration (months). This analysis determines whether biological sex significantly modifies the response to micro-osteoperforation or photobiomodulation therapy during orthodontic canine retraction.

    Time frame: 12 months

  3. Maxillary canine distal movement

    Distance of canine movement measured in millimeters from study models/digital scans.

    Time frame: 12 months

  4. Space closure duration

    Time required to achieve complete extraction space closure measured in months.

    Time frame: 12 months

06

Study locations

1 site
07

References and documents

Publications

  • Alhumadi A. Gender-related response to different wavelength low-level laser therapy in orthodontic mandibular canine movement: a split mouth study. 2026. [In press]
  • Goncalves A, Monteiro F, Brantuas S, Basset P, Estevez A, Silva FS, Pinho T. Clinical and preclinical evidence on the bioeffects and movement-related implications of photobiomodulation in the orthodontic tooth movement: A systematic review. Orthod Craniofac Res. 2025 Feb;28(1):12-53. doi: 10.1111/ocr.12841. Epub 2024 Aug 2. PubMed 39096021 ↗
  • Wazwaz F, Seehra J, Carpenter GH, Papageorgiou SN, Cobourne MT. Duration of canine retraction with fixed appliances: A systematic review and meta-analysis. Am J Orthod Dentofacial Orthop. 2023 Feb;163(2):154-172. doi: 10.1016/j.ajodo.2022.08.009. Epub 2022 Dec 1. PubMed 36464569 ↗
  • Hashem BA, El-Hassanein EH, El-Awady AA, Mohamed AA, Hashem MI, Alsarani MM, Hussein FA. Clinical Evaluation of Single Versus Repeated Micro-Osteoperforations During Orthodontic Canine Retraction: A Randomized Clinical Trial. Cureus. 2024 Jan 10;16(1):e52026. doi: 10.7759/cureus.52026. eCollection 2024 Jan. PubMed 38344550 ↗
  • Alikhani M, Raptis M, Zoldan B, Sangsuwon C, Lee YB, Alyami B, Corpodian C, Barrera LM, Alansari S, Khoo E, Teixeira C. Effect of micro-osteoperforations on the rate of tooth movement. Am J Orthod Dentofacial Orthop. 2013 Nov;144(5):639-48. doi: 10.1016/j.ajodo.2013.06.017. PubMed 24182579 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared publicly due to institutional data privacy regulations and patient confidentiality requirements in accordance with the ethical approval conditions granted by the Institutional Review Board. Aggregate summary data and statistical results will be made available through peer-reviewed publication of the study findings. Researchers wishing to access de-identified data for collaborative purposes may submit a formal written request to the corresponding author, subject to approval by the institutional ethics committee and execution of a data sharing agreement.

08

Registry details

Key details

Study ID
NCT07658235
Lead sponsor
Kufa University
Responsible party
Almustafa Alhumadi (lecturer, Kufa University) — Principal investigator
First posted
Jun 18, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Mar 28, 2027 (estimated)
Completion
May 28, 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Almustafa wisam Ahumadi, master
Contact
almusafaw.alhumadi@uokufa.edu.iq
009647821630001

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion